In-Person Access Only | 6.0 CME Credits
Please read: All programs remain free. Registrations will require a credit card as a cancellation hold. A fee of $99 will only be incurred in the event of a no-show or cancellation within 5 days without written confirmation to the Total Health Program Team. Industry representatives—defined as any individual who is employed by, contracted with, owns, or represents a drug, device, diagnostic, or other healthcare-related commercial entity, regardless of clinical credentials or licensure—are not permitted to attend Total Health events as general attendees. Members of industry must contact exhibits@totalhealthoncology.com
Total Health’s 2026 ASCO Direct™ Genitourinary Cancer Conference is an officially licensed ASCO Direct™ meeting. This Post-ASCO Genitourinary Cancers Symposium Review highlights key abstracts from top-rated presentations, providing attendees with direct access to the latest research and strategies in GU oncology education. The accredited meeting will be hosted as an in-person meeting only available exclusively to registered participants.
Conference Agenda
Saturday, March 14, 2026
8:00 AM
Coffee and Exhibits
8:30 AM
Program Chair Welcome
Pedro Barata, MD, MSc, FACP | University Hospitals
8:40 AM
Updates in Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Ravi Madan, MD | Bethesda, MD
9:10 AM
Treatment Sequencing in Metastatic Hormone-Sensitive Prostate Cancer
Atish Choudhury, MD, PhD | Dana-Farber Cancer Institute
9:40 AM
PSMA-Targeted Therapies & Imaging
Ravi Madan, MD | Bethesda, MD
10:10 AM
Breakfast and Exhibits
10:35 AM
My Top Abstracts from ASCO GU 2026
Michael Serzan, MD | Harvard
11:05 AM
Trials That Will Define GU Oncology in the Next 3–5 Years
Pedro Barata, MD, MSc, FACP | University Hospitals
11:35 AM
Panel Discussion: metPC Cases
Pedro Barata, MD, MSc, FACP | University Hospitals
Bradley McGregor, MD | Dana-Farber Cancer Institute
12:10 PM
Lunch and Exhibits
12:25 PM
Non-CME Lunch - Merck WELIREG - Patient Case-Based Learning: Clinical Management of Certain Adult Patients With Advanced RCC
Nancy A. Dawson, MD | Georgetown Lombardi Comprehensive Cancer Center, Washington, DC
1:10 PM
Housekeeping & Survey
1:20 PM
Bladder Preservation Strategies
Sophia Kamran, MD | Massachusetts General Hospital
1:50 PM
Adjourn
Sunday, March 15, 2026
8:00 AM
Coffee and Exhibits
8:30 AM
Program Chair Welcome
Bradley McGregor, MD | Dana-Farber Cancer Institute
8:40 AM
Kidney Cancer Highlights from ASCO GU 2026
Karie Runcie, MD | Columbia University Irving Medical Center
9:10 AM
First-Line Therapy in Metastatic RCC
Neil Shah, MD | Memorial Sloan Kettering Cancer Center
9:40 AM
Breakfast and Exhibits
9:55 AM
Non-CME Breakfast - Sumitomo/Pfizer - A GnRH Antagonist Treatment Option for Advance Prostate Cancer
Pedro Barata, MD MSc, FACP | University Hospitals for Oncology
10:40 AM
Adjuvant Therapy in Localized RCC
Bradley McGregor, MD | Dana-Farber Cancer Institute
11:10 AM
Biomarker-Driven Strategies for RCC
David Gau, PhD | University of Pittsburgh
11:40 AM
Lunch and Exhibits
11:55 AM
Non-CME Lunch - Natera - MRD Monitoring in GU cancers - Bladder, Kidney, Prostate
Dr. Saum Ghodoussipour| Rutgers Robert Wood Johnson Medical School
12:40 PM
Genomic Profiling in GU Malignancies
Xiao Wei, MD, MAS | Dana-Farber Cancer Institute
1:10 PM
Toxicity Management in Immunotherapy & Targeted Therapy
Kriti Mittal, MD, MS | UMass Memorial Health
1:40 PM
RCC Roundtable Discussion
Pedro Barata, MD, MSc, FACP | University Hospitals
Bradley McGregor, MD | Dana-Farber Cancer Institute
Neil Shah, MD | Memorial Sloan Kettering Cancer Center
Michael Serzan, MD | Harvard
2:40 PM
Adjourn
Agenda Subject To Change. All times are EST.
-
Review and analyze the latest therapeutic advances for the treatment and management of GU cancers
Apply new data and therapeutic advances into guideline-driven treatment strategies to improve the care of patients with prostate, bladder, kidney, and other genitourinary cancers
Identify subpopulations of patients with GU cancers most likely to benefit from specific treatment plans based on prognostic or predictive markers
Evaluate the role of circulating tumor DNA (ctDNA) and minimal residual disease (MRD) in GU cancers
-
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and Total Health. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Nurses (ANCC) Credit Designation
Amedco LLC designates this activity for a maximum of 6.0 ANCC contact hours.
Physicians (ACCME) Credit Designation
Amedco LLC designates this live activity for a maximum of 6.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Pharmacists and Pharmacy Technicians (ACPE) Credit Designation
Amedco LLC designates this activity for a maximum of 6.0 knowledge-based CPE contact hours.
NOTE to Pharmacists: The only official Statement of Credit is the one you pull from CPE Monitor. You must request your certificate within 30 days of your participation in the activity to meet the deadline for submission to CPE Monitor.
-
Free registration for all healthcare providers
Expert sessions that present the most clinically relevant data, research, and clinical strategies
Real-time discussion and debate
Networking with peers, colleagues, and medical professionals
Access to the latest industry information and resources